463. Safety and Biodistribution Study of rAAV2tYF-CB-hRS1 in RS1-deficient Mice

Guo-jie Ye(Applied Genetic Technologies (United States)), Jeffrey D. Chulay(Research Triangle Park Foundation), Thomas J. Conlon(Adelson Foundation), Peter Sonnentag(Covance (United States)), Kirsten Erger(University of Florida), David R. Knop(Applied Genetic Technologies (United States)), Kellie Howard(LabCorp (United States)), Niraj Tripathi Tripathi(Covance (United States)), Alok Sharma
Molecular Therapy
May 1, 2015
10.1016/s1525-0016(16)34072-2
Cited by 0

Related Papers

Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400
Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism
|Journal of Virology|2000|392
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
|Proceedings of the National Academy of Sciences|2009|322
Human <i>RPE65</i> Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year
|Human Gene Therapy|2009|312